Publication: Mepacrine accumulation during treatment of chloroquine-resistant falciparum malaria
Issued Date
1988-01-01
Resource Type
ISSN
00034983
Other identifier(s)
2-s2.0-0023889014
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Annals of Tropical Medicine and Parasitology. Vol.82, No.2 (1988), 107-112
Suggested Citation
S. Looareesuwan, R. E. Phillips, G. Edwards, C. L. Rodick, P. Chanthavanich, W. Supanaranond, D. A. Warrell Mepacrine accumulation during treatment of chloroquine-resistant falciparum malaria. Annals of Tropical Medicine and Parasitology. Vol.82, No.2 (1988), 107-112. doi:10.1080/00034983.1988.11812216 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/15572
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Mepacrine accumulation during treatment of chloroquine-resistant falciparum malaria
Other Contributor(s)
Abstract
Oral mepacrine dihydrochloride, 200 mg (158 mg of the base) six-hourly for five doses followed by 100 mg (79 mg of the base) eight-hourly for six days (half dosage for those ≤ 50 kg) was given to 21 patients with high-grade chloroquine-resistant falciparum malaria in eastern Thailand. Fifteen patients (71%) had a clinical response [fever clearance time of 81 ± 35 hours (mean ± SD)] and 13 (62%) had complete clearance of parasitaemia (clearance time 92 ± 42 hours). Two patients were cured, but 11 patients returned with recurrent parasitaemia between 11 and 40 days after starting treatment. Five patients had an R2 response and three had an R3 response. Mepacrine retains some activity against chloroquine-resistant falciparum malaria but it cannot be recommended for use in Thailand. The doses used, which are those also recommended for giardiasis, led to progressive and potentially toxic mepacrine accumulation. Further evaluation of regimens which produce safer plasma concentration profiles is needed.